Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1768MR)

This product GTTS-WQ1768MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1768MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12240MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ6867MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ4485MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-931699
GTTS-WQ9481MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-5401
GTTS-WQ3334MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ6545MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ5487MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP 6038
GTTS-WQ15927MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW